Study for the effect of blood glucose and metabolic risk factors by switching Sulfonylurea to SGLT2 inhibitor in patients with type 2 diabetes. -prospective observational study
Phase 4
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000016347
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1)Hypersensitivity to Ipragliflozine 2)Uncontrolled diabetic retinopathy 3)Severe liver dysfunction,renal dysfunction,or heart failure 4)Pregnancy,nursing woman or possibly pregnant woman 5)Severe diabetic ketosis,diabetic coma 6)Severe infection,pre and post operation,severe trauma 7)Deficiency of insulin secretion (fasting CPR <0.5 ng/ml) 8) Patients who are inadequate to enter this study due to uncontrolled diet therapy or the other reasons by physician's judgments
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of hypoglycemia and glycemic control
- Secondary Outcome Measures
Name Time Method Weight, BMI, Waist, Lipid metabolism, Blood pressure,Liver function, Complete blood count, renal function, electrolyte Dose and period of Sulfonylurea before clinical trial, Dose change of Sulfonylurea, Change of insulin dose (only patients using insulin)